Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.90
NAS:RGEN's Cash to Debt is ranked lower than
71% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. NAS:RGEN: 1.90 )
Ranked among companies with meaningful Cash to Debt only.
NAS:RGEN' s Cash to Debt Range Over the Past 10 Years
Min: 1.9  Med: No Debt Max: No Debt
Current: 1.9
Equity to Asset 0.58
NAS:RGEN's Equity to Asset is ranked lower than
61% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:RGEN: 0.58 )
Ranked among companies with meaningful Equity to Asset only.
NAS:RGEN' s Equity to Asset Range Over the Past 10 Years
Min: 0.58  Med: 0.92 Max: 0.98
Current: 0.58
0.58
0.98
Interest Coverage 6.57
NAS:RGEN's Interest Coverage is ranked lower than
88% of the 458 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:RGEN: 6.57 )
Ranked among companies with meaningful Interest Coverage only.
NAS:RGEN' s Interest Coverage Range Over the Past 10 Years
Min: 6.57  Med: 443.8 Max: 3988
Current: 6.57
6.57
3988
F-Score: 5
Z-Score: 6.35
M-Score: -2.99
WACC vs ROIC
9.87%
13.60%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 14.44
NAS:RGEN's Operating margin (%) is ranked higher than
83% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. NAS:RGEN: 14.44 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:RGEN' s Operating margin (%) Range Over the Past 10 Years
Min: -27.5  Med: 14.85 Max: 186.01
Current: 14.44
-27.5
186.01
Net-margin (%) 6.89
NAS:RGEN's Net-margin (%) is ranked higher than
79% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. NAS:RGEN: 6.89 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:RGEN' s Net-margin (%) Range Over the Past 10 Years
Min: -19.38  Med: 12.03 Max: 192.3
Current: 6.89
-19.38
192.3
ROE (%) 4.92
NAS:RGEN's ROE (%) is ranked higher than
81% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. NAS:RGEN: 4.92 )
Ranked among companies with meaningful ROE (%) only.
NAS:RGEN' s ROE (%) Range Over the Past 10 Years
Min: -6.01  Med: 7.78 Max: 82.79
Current: 4.92
-6.01
82.79
ROA (%) 3.46
NAS:RGEN's ROA (%) is ranked higher than
83% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. NAS:RGEN: 3.46 )
Ranked among companies with meaningful ROA (%) only.
NAS:RGEN' s ROA (%) Range Over the Past 10 Years
Min: -5.6  Med: 6.72 Max: 75.79
Current: 3.46
-5.6
75.79
ROC (Joel Greenblatt) (%) 45.13
NAS:RGEN's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. NAS:RGEN: 45.13 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:RGEN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -97.28  Med: 46.87 Max: 1148.92
Current: 45.13
-97.28
1148.92
Revenue Growth (3Y)(%) 7.70
NAS:RGEN's Revenue Growth (3Y)(%) is ranked higher than
57% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. NAS:RGEN: 7.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:RGEN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -42.9  Med: 24.5 Max: 45.6
Current: 7.7
-42.9
45.6
EBITDA Growth (3Y)(%) 4.20
NAS:RGEN's EBITDA Growth (3Y)(%) is ranked higher than
55% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. NAS:RGEN: 4.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:RGEN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -64.8  Med: 4.2 Max: 103.8
Current: 4.2
-64.8
103.8
EPS Growth (3Y)(%) -14.60
NAS:RGEN's EPS Growth (3Y)(%) is ranked lower than
63% of the 511 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. NAS:RGEN: -14.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:RGEN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 2.15 Max: 108
Current: -14.6
0
108
» NAS:RGEN's 10-Y Financials

Financials (Next Earnings Date: 2017-02-24)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

RGEN Guru Trades in Q4 2015

Paul Tudor Jones 12,810 sh (+34.40%)
RS Investment Management Sold Out
Joel Greenblatt 23,952 sh (-5.66%)
Jim Simons 782,104 sh (-10.60%)
» More
Q1 2016

RGEN Guru Trades in Q1 2016

Chuck Royce 100,000 sh (New)
Columbia Wanger 604,635 sh (New)
Joel Greenblatt 37,195 sh (+55.29%)
Jim Simons 982,404 sh (+25.61%)
Paul Tudor Jones 9,490 sh (-25.92%)
» More
Q2 2016

RGEN Guru Trades in Q2 2016

Joel Greenblatt 59,717 sh (+60.55%)
Chuck Royce 159,000 sh (+59.00%)
Paul Tudor Jones 13,444 sh (+41.66%)
Columbia Wanger 800,877 sh (+32.46%)
Jim Simons 1,124,804 sh (+14.50%)
» More
Q3 2016

RGEN Guru Trades in Q3 2016

Joel Greenblatt 140,516 sh (+135.30%)
Chuck Royce 199,000 sh (+25.16%)
Paul Tudor Jones Sold Out
Jim Simons 1,077,700 sh (-4.19%)
Columbia Wanger 559,471 sh (-30.14%)
» More
» Details

Insider Trades

Latest Guru Trades with RGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:INVA, NAS:AMAG, NAS:XNCR, OTCPK:SXMDF, NAS:DERM, NAS:PTLA, OTCPK:PFSCF, OTCPK:MPSYY, NAS:BGNE, NYSE:EBS, NAS:CHRS, NAS:FWP, NAS:AIMT, NAS:FOLD, NAS:BPMC, NAS:CORT, NAS:ALDR, NAS:MGNX, NAS:ACOR, NAS:ZIOP » details
Traded in other countries:RGN.Germany,
Repligen Corp is a life sciences company engaged in the development, manufacture & sale of consumable bioprocessing products for life sciences companies & biopharmaceutical manufacturing companies. It also supplies growth factor products.

Repligen Corp was incorporated in May 1981, under the laws of the State of Delaware. The Company is a life sciences company that develops, manufactures and markets consumable bioprocessing products for life sciences companies and biopharmaceutical manufacturing companies. It is also engaged in the manufacture of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug. The Company also supplies growth factor products used to increase cell culture productivity during the biomanufacturing process. In the burgeoning area of biomanufacturing technologies, it has developed and currently markets a series of OPUS or Open-Platform, User-Specified chromatography columns for use in clinical-scale manufacturing. The Company manufactures and sells Protein A and growth factors to life sciences companies under long-term supply agreements and sell its chromatography columns, as well as media and quality test kits, directly to biopharmaceutical companies or contract manufacturing organizations. It manufactures seven forms of commercial scale Protein A including native Protein A for life sciences companies under long-term supply agreements which expire between 2016 and 2021. On December 28, 2012, it out-licensed its SMA program, led by RG3039, to Pfizer Inc. On January 21, 2014, it also out-licensed its histone deacetylase inhibitor portfolio which includes the Friedreich's ataxia program, to BioMarin Pharmaceuticals Inc., or BioMarin. The Company has developed RG1068, a synthetic human hormone for the improved detection of pancreatic duct abnormalities in combination with magnetic resonance imaging in patients with pancreatitis and potentially other pancreatic diseases. It conducts manufacturing in Waltham and at its facility in Lund, Sweden. It sells its bioprocessing products through direct sales force to partners such as GE Healthcare, EMD Millipore, Sigma Aldrich and to distributors in certain foreign markets.

Ratios

vs
industry
vs
history
P/E(ttm) 165.32
RGEN's P/E(ttm) is ranked lower than
92% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 27.27 vs. RGEN: 165.32 )
Ranked among companies with meaningful P/E(ttm) only.
RGEN' s P/E(ttm) Range Over the Past 10 Years
Min: 3.19  Med: 62.63 Max: 99999999.99
Current: 165.32
3.19
99999999.99
PE(NRI) 165.32
RGEN's PE(NRI) is ranked lower than
92% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 27.60 vs. RGEN: 165.32 )
Ranked among companies with meaningful PE(NRI) only.
RGEN' s PE(NRI) Range Over the Past 10 Years
Min: 3.19  Med: 62.63 Max: 99999999.99
Current: 165.32
3.19
99999999.99
P/B 6.42
RGEN's P/B is ranked lower than
72% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. RGEN: 6.42 )
Ranked among companies with meaningful P/B only.
RGEN' s P/B Range Over the Past 10 Years
Min: 1.42  Med: 2.83 Max: 12.19
Current: 6.42
1.42
12.19
P/S 10.60
RGEN's P/S is ranked higher than
50% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. RGEN: 10.60 )
Ranked among companies with meaningful P/S only.
RGEN' s P/S Range Over the Past 10 Years
Min: 2.73  Med: 6.78 Max: 20.38
Current: 10.6
2.73
20.38
PFCF 219.65
RGEN's PFCF is ranked lower than
93% of the 123 Companies
in the Global Biotechnology industry.

( Industry Median: 24.25 vs. RGEN: 219.65 )
Ranked among companies with meaningful PFCF only.
RGEN' s PFCF Range Over the Past 10 Years
Min: 3.2  Med: 36.6 Max: 756.91
Current: 219.65
3.2
756.91
POCF 120.82
RGEN's POCF is ranked lower than
92% of the 186 Companies
in the Global Biotechnology industry.

( Industry Median: 19.60 vs. RGEN: 120.82 )
Ranked among companies with meaningful POCF only.
RGEN' s POCF Range Over the Past 10 Years
Min: 3.14  Med: 34.25 Max: 99999999.99
Current: 120.82
3.14
99999999.99
EV-to-EBIT 72.35
RGEN's EV-to-EBIT is ranked lower than
86% of the 252 Companies
in the Global Biotechnology industry.

( Industry Median: 19.98 vs. RGEN: 72.35 )
Ranked among companies with meaningful EV-to-EBIT only.
RGEN' s EV-to-EBIT Range Over the Past 10 Years
Min: -633.3  Med: 14.6 Max: 650.3
Current: 72.35
-633.3
650.3
EV-to-EBITDA 52.83
RGEN's EV-to-EBITDA is ranked lower than
82% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 16.24 vs. RGEN: 52.83 )
Ranked among companies with meaningful EV-to-EBITDA only.
RGEN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -329.8  Med: 16.5 Max: 466
Current: 52.83
-329.8
466
Shiller P/E 92.54
RGEN's Shiller P/E is ranked lower than
69% of the 58 Companies
in the Global Biotechnology industry.

( Industry Median: 48.79 vs. RGEN: 92.54 )
Ranked among companies with meaningful Shiller P/E only.
RGEN' s Shiller P/E Range Over the Past 10 Years
Min: 44.76  Med: 82.04 Max: 470
Current: 92.54
44.76
470
Current Ratio 10.89
RGEN's Current Ratio is ranked higher than
79% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. RGEN: 10.89 )
Ranked among companies with meaningful Current Ratio only.
RGEN' s Current Ratio Range Over the Past 10 Years
Min: 4.48  Med: 9.53 Max: 44.57
Current: 10.89
4.48
44.57
Quick Ratio 9.68
RGEN's Quick Ratio is ranked higher than
76% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. RGEN: 9.68 )
Ranked among companies with meaningful Quick Ratio only.
RGEN' s Quick Ratio Range Over the Past 10 Years
Min: 4.2  Med: 8.62 Max: 43.88
Current: 9.68
4.2
43.88
Days Inventory 166.50
RGEN's Days Inventory is ranked lower than
62% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 128.70 vs. RGEN: 166.50 )
Ranked among companies with meaningful Days Inventory only.
RGEN' s Days Inventory Range Over the Past 10 Years
Min: 87.98  Med: 145.49 Max: 166.5
Current: 166.5
87.98
166.5
Days Sales Outstanding 55.10
RGEN's Days Sales Outstanding is ranked higher than
55% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. RGEN: 55.10 )
Ranked among companies with meaningful Days Sales Outstanding only.
RGEN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 6.73  Med: 22.84 Max: 55.1
Current: 55.1
6.73
55.1
Days Payable 40.96
RGEN's Days Payable is ranked lower than
63% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. RGEN: 40.96 )
Ranked among companies with meaningful Days Payable only.
RGEN' s Days Payable Range Over the Past 10 Years
Min: 24.96  Med: 67.66 Max: 161.29
Current: 40.96
24.96
161.29

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.80
RGEN's 3-Year Average Share Buyback Ratio is ranked higher than
85% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. RGEN: -1.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RGEN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -18  Med: -1.8 Max: 0.3
Current: -1.8
-18
0.3

Valuation & Return

vs
industry
vs
history
Price/Net Cash 17.57
RGEN's Price/Net Cash is ranked lower than
78% of the 518 Companies
in the Global Biotechnology industry.

( Industry Median: 6.05 vs. RGEN: 17.57 )
Ranked among companies with meaningful Price/Net Cash only.
RGEN' s Price/Net Cash Range Over the Past 10 Years
Min: 1.93  Med: 5.79 Max: 30.8
Current: 17.57
1.93
30.8
Price/Net Current Asset Value 10.46
RGEN's Price/Net Current Asset Value is ranked lower than
70% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 5.53 vs. RGEN: 10.46 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
RGEN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.69  Med: 4.67 Max: 18.34
Current: 10.46
1.69
18.34
Price/Tangible Book 9.06
RGEN's Price/Tangible Book is ranked lower than
75% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. RGEN: 9.06 )
Ranked among companies with meaningful Price/Tangible Book only.
RGEN' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.52  Med: 3.48 Max: 15.04
Current: 9.06
1.52
15.04
Price/Projected FCF 3.66
RGEN's Price/Projected FCF is ranked lower than
55% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 2.84 vs. RGEN: 3.66 )
Ranked among companies with meaningful Price/Projected FCF only.
RGEN' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.69  Med: 1.13 Max: 6.15
Current: 3.66
0.69
6.15
Price/Median PS Value 1.56
RGEN's Price/Median PS Value is ranked lower than
77% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. RGEN: 1.56 )
Ranked among companies with meaningful Price/Median PS Value only.
RGEN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.45  Med: 1.15 Max: 10.04
Current: 1.56
0.45
10.04
Price/Graham Number 8.14
RGEN's Price/Graham Number is ranked lower than
89% of the 194 Companies
in the Global Biotechnology industry.

( Industry Median: 2.38 vs. RGEN: 8.14 )
Ranked among companies with meaningful Price/Graham Number only.
RGEN' s Price/Graham Number Range Over the Past 10 Years
Min: 0.54  Med: 3.23 Max: 11.18
Current: 8.14
0.54
11.18
Earnings Yield (Greenblatt) (%) 1.39
RGEN's Earnings Yield (Greenblatt) (%) is ranked higher than
77% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. RGEN: 1.39 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RGEN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 2.45 Max: 9.9
Current: 1.39
0.2
9.9

More Statistics

Revenue (TTM) (Mil) $100.4
EPS (TTM) $ 0.19
Beta1.00
Short Percentage of Float13.04%
52-Week Range $20.07 - 34.06
Shares Outstanding (Mil)33.83
» More Articles for NAS:RGEN

Headlines

Articles On GuruFocus.com
Repligen Corp. Reports Operating Results (10-Q) Feb 09 2011 
Repligen Corp. Reports Operating Results (10-Q) Nov 02 2010 
Repligen Corp. Reports Operating Results (10-Q) Aug 05 2010 
Repligen Corp. Reports Operating Results (10-Q) Feb 04 2010 
Repligen Corp. Reports Operating Results (10-Q) Nov 05 2009 
Repligen Corp. Reports Operating Results (10-Q) Feb 06 2009 

More From Other Websites
Repligen Corp. breached its 50 day moving average in a Bullish Manner : RGEN-US : November 11, 2016 Nov 11 2016
REPLIGEN CORP Financials Nov 10 2016
Repligen to Participate in Stephens Inc. Fall Investment Conference 2016 Nov 07 2016
Edited Transcript of RGEN earnings conference call or presentation 3-Nov-16 12:30pm GMT Nov 03 2016
REPLIGEN CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 03 2016
Repligen meets 3Q profit forecasts Nov 03 2016
Repligen meets 3Q profit forecasts Nov 03 2016
Repligen Reports Third Quarter 2016 Financial Results Nov 03 2016
Repligen Reports Third Quarter 2016 Financial Results Nov 03 2016
Q3 2016 Repligen Corp Earnings Release - Before Market Open Nov 03 2016
Repligen to Report Third Quarter 2016 Financial Results Oct 20 2016
Repligen to Report Third Quarter 2016 Financial Results Oct 20 2016
Repligen Hires Ralf Kuriyel as Senior Vice President of Research & Development Oct 18 2016
Repligen Hires Ralf Kuriyel as Senior Vice President of Research & Development Oct 18 2016
Repligen Corp. breached its 50 day moving average in a Bullish Manner : RGEN-US : October 11, 2016 Oct 11 2016
Repligen Launches Single-Use XCell™ ATF System for Bioprocess Intensification Oct 05 2016
Repligen Launches Single-Use XCell™ ATF System for Bioprocess Intensification Oct 05 2016
ETF’s with exposure to Repligen Corp. : October 4, 2016 Oct 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)